Peringatan Keamanan

Symptoms of overdose include abdominal irritation, central nervous system depression, coma, extremely slow heartbeat, heart failure, lethargy, low blood pressure, and wheezing.

Oxprenolol

DB01580

small molecule approved

Deskripsi

A beta-adrenergic antagonist used in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety.

Struktur Molekul 2D

Berat 265.348
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 1-2 hours
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Oral bioavailability is 20-70%.

Metabolisme

Hepatic.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

3 Data
  • 1. Avoid alcohol.
  • 2. Avoid natural licorice.
  • 3. Take with or without food. The absorption is unaffected by food.

Interaksi Obat

1680 Data
Duloxetine The risk or severity of orthostatic hypotension and syncope can be increased when Oxprenolol is combined with Duloxetine.
Levodopa The risk or severity of hypotension and orthostatic hypotension can be increased when Oxprenolol is combined with Levodopa.
Risperidone Oxprenolol may increase the hypotensive activities of Risperidone.
Ceritinib Oxprenolol may increase the bradycardic activities of Ceritinib.
Ivabradine Oxprenolol may increase the bradycardic activities of Ivabradine.
Ruxolitinib Ruxolitinib may increase the bradycardic activities of Oxprenolol.
Alfuzosin Alfuzosin may increase the hypotensive activities of Oxprenolol.
Amifostine Oxprenolol may increase the hypotensive activities of Amifostine.
Diazoxide Diazoxide may increase the hypotensive activities of Oxprenolol.
Methylphenidate Methylphenidate may decrease the antihypertensive activities of Oxprenolol.
Dexmethylphenidate Dexmethylphenidate may decrease the antihypertensive activities of Oxprenolol.
Obinutuzumab Oxprenolol may increase the hypotensive activities of Obinutuzumab.
Pentoxifylline Pentoxifylline may increase the hypotensive activities of Oxprenolol.
Rituximab Oxprenolol may increase the hypotensive activities of Rituximab.
Desmopressin Desmopressin may decrease the antihypertensive activities of Oxprenolol.
Doxapram Doxapram may decrease the antihypertensive activities of Oxprenolol.
Phenmetrazine Phenmetrazine may decrease the antihypertensive activities of Oxprenolol.
Dutasteride Dutasteride may decrease the antihypertensive activities of Oxprenolol.
Finasteride Finasteride may decrease the antihypertensive activities of Oxprenolol.
Epicaptopril Epicaptopril may decrease the antihypertensive activities of Oxprenolol.
1-benzylimidazole 1-benzylimidazole may decrease the antihypertensive activities of Oxprenolol.
Tyramine Tyramine may decrease the antihypertensive activities of Oxprenolol.
Moxisylyte Moxisylyte may decrease the antihypertensive activities of Oxprenolol.
Atipamezole Atipamezole may decrease the antihypertensive activities of Oxprenolol.
Siponimod Siponimod may decrease the antihypertensive activities of Oxprenolol.
Idazoxan Idazoxan may decrease the antihypertensive activities of Oxprenolol.
Tramazoline Tramazoline may decrease the antihypertensive activities of Oxprenolol.
Fenozolone Fenozolone may decrease the antihypertensive activities of Oxprenolol.
Xenon Xenon may decrease the antihypertensive activities of Oxprenolol.
Buflomedil Buflomedil may decrease the antihypertensive activities of Oxprenolol.
Mefenorex Mefenorex may decrease the antihypertensive activities of Oxprenolol.
Quinoline Yellow WS Quinoline Yellow WS may decrease the antihypertensive activities of Oxprenolol.
Selpercatinib Selpercatinib may decrease the antihypertensive activities of Oxprenolol.
Naxitamab Naxitamab may decrease the antihypertensive activities of Oxprenolol.
Buprenorphine Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.
Hydrocodone Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Magnesium sulfate The therapeutic efficacy of Oxprenolol can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Oxprenolol may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.
Mirtazapine Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.
Orphenadrine Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.
Pramipexole Oxprenolol may increase the sedative activities of Pramipexole.
Ropinirole Oxprenolol may increase the sedative activities of Ropinirole.
Rotigotine Oxprenolol may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Oxprenolol.
Sodium oxybate Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.
Thalidomide Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Yohimbine The therapeutic efficacy of Oxprenolol can be increased when used in combination with Yohimbine.
Amiodarone The therapeutic efficacy of Oxprenolol can be increased when used in combination with Amiodarone.
Bupivacaine The serum concentration of Bupivacaine can be increased when it is combined with Oxprenolol.
Dipyridamole Dipyridamole may increase the bradycardic activities of Oxprenolol.
Disopyramide Disopyramide may increase the bradycardic activities of Oxprenolol.
Dronedarone Dronedarone may increase the bradycardic activities of Oxprenolol.
Fingolimod Oxprenolol may increase the bradycardic activities of Fingolimod.
Floctafenine The risk or severity of adverse effects can be increased when Oxprenolol is combined with Floctafenine.
Mepivacaine The serum concentration of Mepivacaine can be increased when it is combined with Oxprenolol.
Methacholine Oxprenolol may increase the bronchoconstrictory activities of Methacholine.
Midodrine The therapeutic efficacy of Midodrine can be decreased when used in combination with Oxprenolol.
Nifedipine The risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Oxprenolol.
Propafenone The risk or severity of adverse effects can be increased when Propafenone is combined with Oxprenolol.
Regorafenib Regorafenib may increase the bradycardic activities of Oxprenolol.
Reserpine Reserpine may increase the hypotensive activities of Oxprenolol.
Deserpidine Deserpidine may increase the hypotensive activities of Oxprenolol.
Guanethidine Guanethidine may increase the hypotensive activities of Oxprenolol.
Rivastigmine Oxprenolol may increase the bradycardic activities of Rivastigmine.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Oxprenolol.
Atomoxetine The metabolism of Atomoxetine can be decreased when combined with Oxprenolol.
Mirabegron The serum concentration of Oxprenolol can be increased when it is combined with Mirabegron.
Nicorandil Nicorandil may increase the hypotensive activities of Oxprenolol.
Molsidomine Molsidomine may increase the hypotensive activities of Oxprenolol.
Insulin argine Oxprenolol may increase the hypoglycemic activities of Insulin argine.
Dorzolamide Dorzolamide may increase the hypotensive activities of Oxprenolol.
Bimatoprost Bimatoprost may increase the hypotensive activities of Oxprenolol.
Unoprostone Oxprenolol may increase the hypotensive activities of Unoprostone.
Torasemide Torasemide may increase the hypotensive activities of Oxprenolol.
Chlorthalidone Chlorthalidone may increase the hypotensive activities of Oxprenolol.
Nitroprusside Nitroprusside may increase the hypotensive activities of Oxprenolol.
Minoxidil Minoxidil may increase the hypotensive activities of Oxprenolol.
Metolazone Metolazone may increase the hypotensive activities of Oxprenolol.
Mecamylamine Mecamylamine may increase the hypotensive activities of Oxprenolol.
Furosemide Furosemide may increase the hypotensive activities of Oxprenolol.
Nitroglycerin Nitroglycerin may increase the hypotensive activities of Oxprenolol.
Fenoldopam Fenoldopam may increase the hypotensive activities of Oxprenolol.
Hydralazine Hydralazine may increase the hypotensive activities of Oxprenolol.
Remikiren Remikiren may increase the hypotensive activities of Oxprenolol.
Guanadrel Guanadrel may increase the hypotensive activities of Oxprenolol.
Bosentan Bosentan may increase the hypotensive activities of Oxprenolol.
Candoxatril Candoxatril may increase the hypotensive activities of Oxprenolol.
Cryptenamine Cryptenamine may increase the hypotensive activities of Oxprenolol.
Pentolinium Pentolinium may increase the hypotensive activities of Oxprenolol.

Target Protein

Beta-1 adrenergic receptor ADRB1
Beta-3 adrenergic receptor ADRB3
Beta-2 adrenergic receptor ADRB2

Referensi & Sumber

Artikel (PubMed)
  • PMID: 2897304
    McDevitt DG: Comparison of pharmacokinetic properties of beta-adrenoceptor blocking drugs. Eur Heart J. 1987 Dec;8 Suppl M:9-14.

Contoh Produk & Brand

Produk: 5 • International brands: 2
Produk
  • Slow Trasicor Tab 160mg
    Tablet, extended release • 160 mg / tab • Oral • Canada • Approved
  • Slow Trasicor Tab 80mg
    Tablet, extended release • 80 mg / tab • Oral • Canada • Approved
  • Trasicor Tab 20mg
    Tablet • 20 mg / tab • Oral • Canada • Approved
  • Trasicor Tab 40mg
    Tablet • 40 mg • Oral • Canada • Approved
  • Trasicor Tab 80mg
    Tablet • 80 mg • Oral • Canada • Approved
International Brands
  • Trasacor
  • Trasicor

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul